<DOC>
	<DOCNO>NCT01562821</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial evaluate haemostatic efficacy activate recombinant human factor VII cirrhotic patient schedule undergo partial hepatectomy due liver cancer benign tumour .</brief_summary>
	<brief_title>Safety Efficacy Activated Recombinant Human Factor VII Cirrhotic Patients Undergoing Partial Hepatectomy</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Cirrhosis ( ChildTurcotte Score A , B , C ) Scheduled undergo partial hepatectomy due liver cancer benign tumours Portal vein thrombosis Clinically document DVT ( deep venous thrombosis ) Clinically document symptom severe cardiovascular disease and/or previous myocardial/pulmonary infarction stroke Present renal insufficiency require dialysis</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>